These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 21362752)

  • 1. Illness perceptions in patients with systemic lupus erythematosus and proliferative lupus nephritis.
    Daleboudt GM; Broadbent E; Berger SP; Kaptein AA
    Lupus; 2011 Mar; 20(3):290-8. PubMed ID: 21362752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life in patients with systemic lupus erythematosus and proliferative lupus nephritis.
    Daleboudt GM; Berger SP; Broadbent E; Kaptein AA
    Psychol Health Med; 2011 Aug; 16(4):393-404. PubMed ID: 21749237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.
    Gunnarsson I; Sundelin B; Jónsdóttir T; Jacobson SH; Henriksson EW; van Vollenhoven RF
    Arthritis Rheum; 2007 Apr; 56(4):1263-72. PubMed ID: 17393458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine/ methylprednisolone in a randomized controlled trial.
    Grootscholten C; Snoek FJ; Bijl M; van Houwelingen HC; Derksen RH; Berden JH;
    J Rheumatol; 2007 Aug; 34(8):1699-707. PubMed ID: 17659757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis.
    Grootscholten C; Bajema IM; Florquin S; Steenbergen EJ; Peutz-Kootstra CJ; Goldschmeding R; Bijl M; Hagen EC; Van Houwelingen HC; Derksen RH; Berden JH;
    Arthritis Rheum; 2007 Mar; 56(3):924-37. PubMed ID: 17328070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of illness perceptions on sexual functioning in patients with systemic lupus erythematosus.
    Daleboudt GM; Broadbent E; McQueen F; Kaptein AA
    J Psychosom Res; 2013 Mar; 74(3):260-4. PubMed ID: 23438719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus.
    Petri M; Jones RJ; Brodsky RA
    Arthritis Rheum; 2003 Jan; 48(1):166-73. PubMed ID: 12528116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis.
    Mok CC; Ying KY; Tang S; Leung CY; Lee KW; Ng WL; Wong RW; Lau CS
    Arthritis Rheum; 2004 Aug; 50(8):2559-68. PubMed ID: 15334470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance.
    Hanly JG; McCurdy G; Fougere L; Douglas JA; Thompson K
    J Rheumatol; 2004 Nov; 31(11):2156-62. PubMed ID: 15517627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; de Ramon Garrido E; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2004 Dec; 50(12):3934-40. PubMed ID: 15593207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice.
    Ogawa H; Kameda H; Amano K; Takeuchi T
    Lupus; 2010 Feb; 19(2):162-9. PubMed ID: 19952069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of interleukin-1 receptor antagonist in patients with systemic lupus erythematosus could predict renal manifestation of the disease.
    Brugos B; Kiss E; Dul C; Gubisch W; Szegedi G; Sipka S; Zeher M
    Hum Immunol; 2010 Sep; 71(9):874-7. PubMed ID: 20538031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus.
    Brunner HI; Gladman DD; Ibañez D; Urowitz MD; Silverman ED
    Arthritis Rheum; 2008 Feb; 58(2):556-62. PubMed ID: 18240232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
    Mok CC; Ying KY; Ng WL; Lee KW; To CH; Lau CS; Wong RW; Au TC
    Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of antiphospholipid antibodies following cyclophosphamide therapy in patients with systemic lupus erythematosus.
    Vlachoyiannopoulos PG; Toya SP; Katsifis G; Zintzaras E; Tzioufas AG; Moutsopoulos HM
    J Rheumatol; 2008 Sep; 35(9):1768-75. PubMed ID: 18634157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the quality of life of patients with systemic lupus erythematosus with and without endstage renal disease.
    Vu TV; Escalante A
    J Rheumatol; 1999 Dec; 26(12):2595-601. PubMed ID: 10606368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].
    Petrović R; Stojanović R; Novicić-Sasić D; Dimitrijević J; Pavlović S; Stojković D; Palić-Obradović D; Stevanović G; Prodanović S
    Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():19-25. PubMed ID: 12583309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeated renal biopsy in proliferative lupus nephritis--predictive role of serum C1q and albuminuria.
    Gunnarsson I; Sundelin B; Heimbürger M; Forslid J; van Vollenhoven R; Lundberg I; Jacobson SH
    J Rheumatol; 2002 Apr; 29(4):693-9. PubMed ID: 11950009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum BLC/CXCL13 concentrations and renal expression of CXCL13/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis.
    Lee HT; Shiao YM; Wu TH; Chen WS; Hsu YH; Tsai SF; Tsai CY
    J Rheumatol; 2010 Jan; 37(1):45-52. PubMed ID: 19955043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.